Session » Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

Date: Sunday, November 13, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1370

Abatacept in the Treatment of Refractory Juvenile Dermatomyositis

1:00PM-3:00PM: Abstract Number: 1365

Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database

1:00PM-3:00PM: Abstract Number: 1379

Association of HLA Alleles with Specific Auto-antibodies in an Ancestrally Diverse Population of Childhood Systemic Lupus Erythematosus (SLE)

1:00PM-3:00PM: Abstract Number: 1378

Childhood-onset Systemic Lupus Erythematosus: Long-term Outcomes in a Large Multi-ethnic Ontario Cohort

1:00PM-3:00PM: Abstract Number: 1385

Clinical and Serologic Characterization of Juvenile Systemic Sclerosis Overlap Disease

1:00PM-3:00PM: Abstract Number: 1360

Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide

1:00PM-3:00PM: Abstract Number: 1366

Developing a Mobile App to Facilitate Disease Activity Assessment in Localized Scleroderma

1:00PM-3:00PM: Abstract Number: 1380

Development of Core and Expanded Datasets to Align Registries and Advance International Collaborative Research for Childhood-onset Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1383

Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity

1:00PM-3:00PM: Abstract Number: 1364

Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the the Juvenile Scleroderma Inception Cohort

1:00PM-3:00PM: Abstract Number: 1384

Echocardiographic Screening in Childhood Onset Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1376

Eculizumab Is Safe as an Adjunctive Therapy in Systemic Lupus Erythematosus with Severe Refractory Nephritis with or Without Thrombotic Microangiopathy in Children

1:00PM-3:00PM: Abstract Number: 1361

Factors Associated with Medication-Free Remission in Juvenile Dermatomyositis

1:00PM-3:00PM: Abstract Number: 1381

Health Related Quality of Life in Children with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1368

How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey

1:00PM-3:00PM: Abstract Number: 1363

Impact of SARS-CoV-2 on the Clinical Presentation of Juvenile Idiopathic Inflammatory Myopathies

1:00PM-3:00PM: Abstract Number: 1373

Increased Patient Contact May Mitigate Flares Among jSLE Patients

1:00PM-3:00PM: Abstract Number: 1382

Juvenile Eosinophilic Fasciitis: A Single-Center Cohort

1:00PM-3:00PM: Abstract Number: 1371

Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1377

Mental Health Screening in Juvenile Myositis: Preliminary Analysis of a Multicenter Pilot Study

1:00PM-3:00PM: Abstract Number: 1367

Patient and Physician Reported Outcomes of Juvenile Systemic Sclerosis Patients Significantly Improve over 12 Months Observation Period in the Juvenile Systemic Scleroderma Inception Cohort

1:00PM-3:00PM: Abstract Number: 1374

Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study

1:00PM-3:00PM: Abstract Number: 1375

Short-term Efficacy of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis

1:00PM-3:00PM: Abstract Number: 1369

Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting

1:00PM-3:00PM: Abstract Number: 1372

Telemedicine Use in the Assessment of Juvenile Dermatomyositis and Polymyositis: A Survey of Caregivers and Patients

1:00PM-3:00PM: Abstract Number: 1386

The Association of Depression with Executive Function Skills and Health-Related Quality of Life in Youth with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1362

Validation of the 2016 ACR/EULAR Myositis Response Criteria in Juvenile Dermatomyositis (JDM) Clinical Trials and Consensus Profiles

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].